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Abstract
Progress in the development of therapeutic interventions to treat or slow the progression of Alzheimer’s disease has been
hampered by lack of efficacy and unforeseen side effects in human clinical trials. This setback highlights the need for new
approaches for pre-clinical testing of possible interventions. Systems modelling is becoming increasingly recognised as a
valuable tool for investigating molecular and cellular mechanisms involved in ageing and age-related diseases. However,
there is still a lack of awareness of modelling approaches in many areas of biomedical research. We previously developed a
stochastic computer model to examine some of the key pathways involved in the aggregation of amyloid-beta (Ab) and the
micro-tubular binding protein tau. Here we show how we extended this model to include the main processes involved in
passive and active immunisation against Ab and then demonstrate the effects of this intervention on soluble Ab, plaques,
phosphorylated tau and tangles. The model predicts that immunisation leads to clearance of plaques but only results in
small reductions in levels of soluble Ab, phosphorylated tau and tangles. The behaviour of this model is supported by
neuropathological observations in Alzheimer patients immunised against Ab. Since, soluble Ab, phosphorylated tau and
tangles more closely correlate with cognitive decline than plaques, our model suggests that immunotherapy against Ab
may not be effective unless it is performed very early in the disease process or combined with other therapies.
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Introduction
Alzheimer’s disease (AD) is characterised by aggregation of Ab
and tau proteins in the brain accompanied by glial cell activation
together with synaptic and neuronal loss (reviewed in [1]). There is
still no effective treatment which targets the underlying neurode-
generation in AD although many interventions are currently being
tested. For example, a phase 11a clinical trial of PBT2, a metal-
protein attenuating compound, has shown preliminary promising
results although longer and larger trials are needed [2]. Based on
the amyloid cascade hypothesis and promising experimental
studies [3], some clinical trials of Ab immunotherapy have shown
hints of slowed deterioration in cognitive function [4,5]. Unfor-
tunately a small proportion of subjects treated with the first Ab
immunotherapy agent (AN1792) [6] developed aseptic meningo-
encephalitis and the trial had to be halted [7] and side effects
remain a problem with agents currently in trials [8]. These side
effects were unexpected and were not predicted by the pre-clinical
animal models, demonstrating that animal models of AD do not
replicate the complexity of the human disease [9]. Despite this
serious drawback, animal models continue to be used extensively
in the search for new therapies. We suggest that there is now a
great need to develop new approaches to investigate possible new
interventions. Mathematical modelling and computer simulation
are relatively new approaches in the medical sciences but their
potential as a useful complementary tool is being increasingly
recognised.
Despite the problems associated with the clinical trials, a wealth
of valuable data has been obtained and detailed analysis has been
carried out. For example, neuropathological studies of patients
with AD who were immunised against Ab have shown that a
reduction in Ab plaques occurs [10–13] and this observation has
subsequently been confirmed in vivo by amyloid imaging [14].
The actual mechanisms of how immunisation clears Ab are not
fully known but seem to involve phagocytosis of Ab by microglia
[12,13,15] and solubilisation of Ab by antibody binding [10,16].
In support of the amyloid hypothesis, immunotherapy-mediated
removal of Ab is accompanied by a reduction in phospho-tau
[17,18] and of a kinase putatively involved in mediating tau
phosphorylation (GSK3b) [19]. The analysis of this data has
provided the motivation to modify our previous dynamical model
of the molecular mechanisms involved in the initiation and
progression of AD [20] by including processes involved in Ab
immunisation.
As the pathways are complex and many of the mechanisms are
not yet fully understood, it is necessary to make assumptions when
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building the model. There is also controversy over different
mechanisms. This means that our assumptions will not be in
accord with everyone’s point of view.
For example, plaques are considered to be neuroprotective or
having detrimental effects. We assume that Ab can be detrimental
by inducing production of reactive oxygen species (ROS), either as
fibrillar (plaque) or soluble Ab [21,22]. Then ROS increase the
production of p53 which leads to increased activity of GSK3b,
increased phosphorylation of tau and hence the formation of
tangles. Ab may also directly enhance p53 production [23]. We
also assume that soluble Ab may inhibit the proteasome which
would have detrimental effects on cells [24]. The formation of
plaques decreases the pool of soluble Ab and so prevents all these
adverse effects, and is included as a neuroprotective role for
plaques in our model.
Mathematical models of Ab aggregation have been previously
developed (e.g. [25,26])and one in particular has been used to test
interventions [27]. However, all these models have focussed only
on Ab and have not considered the role of tau aggregation which
many consider to be more important than Ab in the disease
process [28–31]. The mechanisms which link Ab and tau are still
not fully known although many suggestions have been made [32–
35]. The novelty of our model resides in that it seeks to not only
examine the effect of interventions on Ab but also how antibodies
against Ab can reduce tau pathology. In order to do this, we
include possible players such as GSK3b, p53 and ROS that may
link these two seemingly independent aggregation pathways as
described in our previous mathematical model [20].
Since many of the mechanisms involved in the protein
aggregation process are inherently random, and the numbers of
molecules involved in many of the reactions we consider are small,
it is more appropriate to use stochastic simulation for our models.
However, the disadvantage of stochastic simulation is that it is very
computer intensive and so we also use deterministic simulators for
examining the effects of different parameters in the model. The
models are represented as biochemical networks and are encoded
in the widely used Systems Biology Markup Language (SBML)
[36,37]. This allows the models to be used in many different
software tools and also allows easy modification as new data and
hypotheses emerge. The models are freely available and provide a
useful resource for researchers seeking new approaches in
investigating the molecular mechanisms involved in AD and to
test possible interventions.
Results
AD model and effect of clearance rate of Ab monomers
on plaque and tangle formation
We used the model to mimic a cellular system whereby soluble
Ab is added to cells and the kinetics of its aggregation are followed
over time scales of days. Therefore we parameterised our model
using data from a cellular system [38]and carried out all the
simulations over a 12 day period. In the experimental setting, after
addition of Ab to cells, aggregates form rapidly and are usually
observed within 24 hours and reach maximum levels by about 2
days. In our computer model, the level of Ab is initially zero, then
monomers are produced and if the production rate is greater than
the degradation rate, the monomer levels increase, form dimers
and may start to aggregate as plaques. The rates for Ab
production and clearance are based on experimental data from
a study showing that the Ab production rate was the same in AD
subjects and age-matched controls (1.86e25 molecules s21) but
that the degradation rate was lower in the AD subjects (1.5e-5s21)
compared to control subjects (2.1e-5s21) [39]. This means that the
ratio of Ab production to Ab degradation is about 1.24 and 0.89
for AD and control subjects respectively, so the ratio of production
to degradation is greater than one in the AD subjects which
explains why Ab levels increase over time. The experimental data
was based on measurements in the cerebral spinal fluid rather than
brain. Although this may be a limitation in the model, it is the
relative rates of production and degradation that are important
rather than their absolute rates since Ab only accumulates if
production is greater than degradation. The Ab production and
degradation rates of the AD subjects was used in our model. We
also tried the normal degradation rate to investigate if our model
would predict less occurrence of plaques. However, since we have
accelerated the aggregation process for a cellular system as
opposed to an ageing human brain, we found that we needed a
much higher degradation rate for Ab than that observed in normal
aged brain [39] in order to prevent high levels of plaques forming
under normal conditions (Figure 1). This is due to the stochastic
simulation used and even if the production rate was lower than the
degradation rate, occasional monomers will be present with the
possibility of starting the aggregation process. If we use a
degradation rate high enough, the model predicts that plaques
never form over a 12 day period (Figure 1D). Using the lower
degradation rate for AD, our model predicts a maximum plaque
size of about 75 molecules reached in 6 days (from the time of
formation) (Figure 1A). Figure 1 show the mean 6 one standard
deviation from the mean and it can be seen that there is variation
in the levels of plaques and tangles, but the differences are not
large (see also Figure S1 for plots of six individual stochastic
simulations). It has been shown that there is high variability in the
level of amyloid plaque content in AD patients with plaques even
being undetected by imaging in some patients [40]. However, we
should point out that by definition a patient cannot have AD
without amyloid plaques and so this data may not be valid. The
model presented here suggests that stochastic effects alone cannot
explain the observed variability. However, the speeding up of the
aggregation process, to mimic a cellular system, may have masked
some of the variability as in a previous model of plaque formation
examined over a period of 100 years, there was a very large
variation in the age at which plaques first appeared [41].
Alternatively there may be effects due to other important factors
such as genetic disposition which are currently missing from the
model.
Simulation of passive immunisation for the treatment of
Alzheimer’s disease
For these simulations, the low degradation rate of Ab (i.e. the
AD rate) was used, so that plaques would form by day 4. In order
to examine the effects of immunisation in the low degradation rate
model, we simulated passive immunisation by adding the
antibodies. The exact mechanisms by which antibodies work is
still not clear and so we modelled three possible effects: enhanced
degradation of soluble Ab, enhanced disaggregation of plaques
and activation of microglia to engulf and phagocytose plaques
[15]. We simulated immunisation by using an event structure in
the SBML code, whereby the species ‘‘antiAb’’ representing
antibodies was set to 50 (the initial value being zero) at a specific
time-point after the beginning of the simulation. If immunisation is
simulated at day 4, when levels of plaques are low prior to the
treatment, then the model predicts that levels of plaques are
reduced and that initially there is a reduction in soluble Ab.
However following the disaggregation of plaques, soluble Ab levels
rise again and levels of plaques start to slowly increase (Figure 2B).
The model also predicts a decrease in levels of phospho tau
immediately after immunisation on day 4 and although levels of
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Figure 1. Model predictions for levels of Ab and tau under normal and AD conditions (no immunisation). The mean curves from 100
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phospho tau continue to increase with time, this occurs at a much
slower rate than prior to immunisation (green curve, Figure 2B).
The reduction in levels of phospho tau by immunisation agrees
with neuropathological data [10]. If immunisation is delayed until
day 8, then levels of plaques are almost at their maximum prior to
treatment, and so the increase of microglial activation is much
more rapid and there is consequently a rapid clearance of plaques
(Figure 2C). However, plaques are not totally cleared and remain
above basal levels as a result of increased ROS in the system.
There is no significant difference in the kinetics of tau
phosphorylation or aggregation. Repeated interventions at day 0
and day 7 prevent plaques reaching high levels (Figure 2D).
However, there is more activated microglia which may be
detrimental due to their effects on ROS. Therefore the model
suggests that an additional intervention to reduce ROS may be
required if repeated immunisations are carried out. The model
predicts that there is slightly slower kinetics in tau phosphorylation
and aggregation with repeated interventions. We hypothesise that
this is due to decreased activation of p53 and GSK3b via ROS
which we confirmed by examining the level of active pools of p53
and GSK3b in the simulation output (data not shown). The model
predicts some cell to cell variation in the model output as shown by
the shaded areas in Figure 2 which represent one standard
deviation from the mean. For example, the regions representing
the mean6 one standard deviation for soluble Ab after
immunization at Day 4 (Figure 2B) compared to no immunization
(Figure 2F) are very similar. This indicates that for a particular cell,
the levels of soluble Ab could be higher after immunisation than
without immunisation. This stochastic variation may explain the
biological variability in responses to immunotherapy [16] and why
some immunised AD patients show increased soluble Ab
compared to AD controls [42].
Simulation of active Ab immunisation for the treatment
of Alzheimer’s disease
We chose to mimic the action of full length Ab42 (AN1792) for
the active immunisation. We assume that this treatment causes
antibody levels to slowly increase and then remain elevated. We
modelled this by assuming that the species ‘‘antiAb’’ is continually
produced and included a reaction for antiAb production. The
model predicts similar results to repeated passive immunisation
(Figure 2E). The results for no immunisation are also shown
(Figure 2F) for comparison.
Simulation of Ab immunisation for the prevention of
Alzheimer’s disease
In order to examine the effects of the possibility of using Ab
immunisation for the prevention of Alzheimer’s disease, we
simulated the addition of antibodies (simulating passive immuni-
sation) at the start at the simulation (before any plaques had
appeared). To do this we set the initial value of antiAb to equal 50.
The model predicts that immunisation at day 0 dramatically
reduced plaques over a 12 day period but had only a small effect
on levels of soluble Ab (orange curve, Figure 2A). This
intervention also predicts slightly lower levels of phospho-tau
(compare green curves in Figure 2A and 2F) in agreement with
neuropathological data [10]. This prediction is due to less Ab-
induced ROS production and so less activation of p53, which
based on biochemical data demonstrating physical association of
p53 with GSK3b and an increase of GSK3b activity in a p53
concentration-dependent manner [43] may result in a decrease in
GSK3b activity.
Effects of immunisation on GSK3b and phospho-tau
Following Ab immunisation we observed a lower GSK3b and a
lower phospho-tau load in AD immunized patients [10,17,19].
Therefore we examined the model predictions on the levels of
GSK3b and phospho-tau under the different interventions. As we
currently do not include GSK3b turnover in our model (there
being no evidence for the regulation of GSK3b at this level), we
examined the levels of active GSK3b since phosphorylation of tau
is dependent on this pool. The model predicts that interventions
which start at day 0 lead to a delay in the increase in GSK3b
activity (Figure 3A) but by day 12 there is very little difference in
active GSK3b pools compared to later interventions. However, if
the immunisation is repeated at day 7, the level of active GSK3b is
lower throughout the 12 day period. The intervention at day 4 and
day 8 show an immediate decrease in active pools of GSK3b after
the simulated immunisation (green and red curves in Figure 3A).
This is due to levels of plaques being fairly high prior to the
immunisation so that microglia are activated, Ab is cleared and
ROS levels also decline (Figure 2 and 3C). The reduction in active
GSK3b also leads to a reduction in phospho-tau (Figure 3B).
Immunisation simulated at any time-point leads to lower GSK3b
compared with no immunisation (black curve vs. coloured curves -
Figure 3A) but there is no significant difference in active GSK3b
pools by day 12 between the different interventions. However,
according to the model, the reduction in active GSK3b at earlier
time-points is not sufficient to significantly reduce levels of
phospho-tau by day 12.
Parameters/reactions which will affect model predictions
Plots of individual simulations show that the cell to cell
variability in levels of Ab, tau and the kinetics of their aggregation
are fairly small (Figure S1). Therefore we used a deterministic
model to carry out parameter scans in COPASI [44]. We first
checked how the deterministic model compared with the stochastic
model for the different interventions and found that there were
some differences due to the low numbers of Ab molecules (Figure
S2). The best agreement between the models occurred for the
intervention on day 4 and so we used this model for the parameter
scans. We varied each parameter in turn from half to double its
initial value and examined the effect on levels of Ab, tau, activated
micoglia and ROS over a 12 day time course. Out of 73
parameters, 22 had no effect, 11 had very small non-significant
effects and 40 had signficant effects on one or more of the species
examined. The latter parameters are directly involved either in the
aggregation process or in the DNA damage response. The results
are summarized in Table 1 and plots from a selection of the key
parameters are shown in Figures S3 and S4. It can be seen that the
parameters which are directly involved in the DNA damage
response effect Ab, tau, activated microglia and ROS simulta-
neoulsy and always in the same direction (i.e. all levels are
increased or decreased in response to the increase in the parameter
value). This means that the model predicts that an increase (or
decrease) in DNA damage results in an increase (or decrease) in
both Ab and tau aggregation. On the other hand, changes in the
stochastic simulations are plotted for different Ab clearance rates. The shaded regions represent the one standard deviation from the mean. A
kdegAbeta= 1.5e-5 s
21), B kdegAbeta= 2.1e-5 s
21), C kdegAbeta= 1.0e-4s
21, D kdegAbeta= 2.0e-4s
21. Key: orange = soluble Ab; blue =Ab plaques;
green=phospho-tau; black = tau tangles; red = activated glia.
doi:10.1371/journal.pone.0073631.g001
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Figure 2. Model predictions for levels of Ab, tau, activated glia under different simulated interventions. The mean curves from 100
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values of parameters which only affect aggregation processes may
affect either Ab and tau aggregation (e.g. production of Ab via
GSK3b, Figure S4B) or only tau aggregation (e.g. tau binding to
microtubules, Figure S3C). We found that there was no parameter
which only affected Ab without affecting tau aggregation. This
suggests that reducing levels of Ab may reduce the formation of
phospho-tau and tangles in support of the amyloid hypothesis
[45,46].
In order to gain more insight we ranked the top 40 parameters
that control the change in the model output. We first ranked them
according to the amount of reduction in the maximum size of
plaques. To do this, we calculated the % change in maximum
plaque size when the parameter value was halved or doubled
compared to the default parameter value. Only 28 parameters
affected plaque size. In 14 cases, increasing the parameter value
reduced plaque size, whereas for the other 14 cases, decreasing the
parameter value reduced plaque size. We ranked the parameters
according to their effect on plaque size in Table 2 where it can be
seen that the parameters involved in Ab production, plaque
growth and plaque disaggregation had the largest effect (see also
Figure S5 for a diagram of the reactions corresponding to the top
28 parameters). Note that kbinGSK3bp53 and krelGSK3bp53 affect Ab
production as we assumed that GSK3b bound to p53 increased
production of Ab. We also ranked the parameters according to
their effect on decreasing levels of soluble Ab, since this species
may also be toxic. We found that each parameter affected plaques
and soluble Ab in the same direction which may be surprising as
for example, we might expect that decreasing plaque size would
lead to an increase in soluble Ab. However, the soluble pool
included monomers and dimers and on closer examination, we
found that levels of dimers did increase when plaques decreased.
However, a reduction in plaque size also reduced levels of ROS
which then led to less Ab production via activatedGSK3b.
Although most of the parameters had similar ranks for plaques and
soluble Ab, (Pearson’s product-moment correlation= 0.493, p-
value = 0.0077, indicating a fairly strong correlation between the
two sets of ranks), there were four notable exceptions. The
parameters for plaque disaggregation and for plaque growth are
ranked 2, 5 and 6 for their effect on plaque size but are ranked 23,
24 and 25 for their effect on soluble Ab. The fourth parameter
kdimer has only a small effect on plaques (ranked 28th) but
decreasing this parameter reduces soluble Ab by nearly 30%
(ranked 4th). This is due to our assumption that monomers are
degraded much more rapidly than dimers (which are only
degraded when bound to antibodies). The parameters correspond-
ing to the addition of antibodies did not affect plaque size in this
analysis as we only looked at maximum plaque size which
occurred before the addition of antibodies.
The effect of parameters on tangle formation and phosphory-
lation of tau are shown in Table 3 and Figure S5. We found that
36 parameters had effects which included all those that had effects
on Ab and in addition 8 parameters that were specific to tau
(kdephosTau, kphosTauGsk3bp53, kbinMTTau, krelMTTau kaggTauP2, kbinAbantiAb,
ksynTau, kdegAntiAb). The two parameters involving antiAb affected tau
and not Ab as maximum levels of Ab occurred before
immunization, whereas our model predicted that tau continued
to increase after this intervention. Increasing the effectiveness of
the treatment had beneficial effects on tau due to the lowering in
ROS (see Figures S3 and S4). It is interesting to note that none of
the parameters that were specific to tau had any effects on Ab level
or its aggregation whereas the reverse was not true. This suggests
that reactions involving tau are downstream of Ab and do not feed
back into the system. The parameters which had most effect on
tangle formation were those that involved phosphorylation of tau
by GSK3b. It may be surprising that the parameters affecting
Mdm2 and p53 ranked so highly but this is because increasing the
binding of Mdm2 to p53 prevents binding of GSK3b to p53 and
lowers the activity of GSK3b. There was very little difference in
the rankings for the parameters that affected tangle formation and
phospho-tau with the top 13 being identical (Pearson’s product-
moment correlation= 0.957, p-value,2.2e-16, indicating a very
strong correlation between the two sets of ranks). Although we
assumed that free pools of unphosphorylated tau could aggregate,
the parameter for aggregation of phosphorylated tau was set to be
10 times higher. Therefore phosphorylation of tau is closely linked
to its aggregation. The other 4 parameters only affected activation
of glia as the maximum plaque size occurred before glia activation.
Increasing the activation rate of glia led to higher levels of
activated glia and a slightly more rapid decline in plaques (data not
shown). However, as plaques decline fairly rapid with the default
parameters, the effect is not significant.
Discussion
We extended our previous model of GSK3 and p53 and their
effects on the aggregation of Ab and tau [33] to include reactions
that describe a simulated immunisation againt Ab. Our approach
is novel as we considered in addition to Ab aggregation, the role of
tau and included other molecular mechanisms which may
contribute to the aggregation process in the ageing brain, and
the effects of Ab intervention. The motivation for extending our
previous model was the observation that immunotherapy can
reduce tau phosphorylation. We wanted to examine whether our
model would also predict this following a simulated immunisation
against Ab. Our modified model included assumptions about the
effects of immunisation on Ab but we did not include any direct
mechanism for the effects on tau. The model includes indirect
interactions between Ab and tau via GSK3b but due to the
complexity of the model, the effects on tau were not obvious prior
to carrying out simulations. Our model predicted reduced tau
phosphorylation after immunisation as observed giving support to
our model assumptions. However, further experimental tests of the
model predictions are required to establish its accuracy. If there is
discrepancy, this will lead to refinement of hypotheses and
modification of the model. This actual process can lead to further
understanding to the underlying mechanisms. Other mechanisms
which may be important and are not currently included in our
model are discussed below.
We chose to mimic the effect of both active immunisation with
full length AB42 (AN1792) and passive immunisation with an
antibody that works by enhancing Ab degradation, plaque
disaggregation and phagocytosis of plaques via activated microg-
lia. There are other newer antibodies such as Solanuzumab which
have different modes of action and so the model would need to be
modified to test these. However, modifications of SBML models
are straight forward to carry out and this could be done in the
stochastic simulations are plotted (six individual runs are shown in Fig. S2). The shaded regions represent the one standard deviation from the mean.
A–D Simulated passive immunisation administered at different time-points: A Day 0; B Day 4; C Day 8; D Repeated immunisation at Day 0 and Day 7. E
Simulated active immunisation. F No immunisation. Key: orange= soluble Ab; blue =Ab plaques; green=phospho-tau; black = tau tangles;
red = activated glia.
doi:10.1371/journal.pone.0073631.g002
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Figure 3. Model predictions for levels of ROS, Gsk3b and phospho-tau under different simulated interventions. The mean curves from
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future. We included the effects of antibodies on soluble Ab and
plaques, the activation of microglia, and the effects of activated
microglia on plaques and levels of ROS. Our model predicted that
immunisation reduces levels of plaques but that pools of soluble Ab
were only reduced by small amounts. The activity of GSK3b and
levels of phospho-tau were both reduced immediately after
immunisation and then remained at fairly constant levels in
accordance with experimental data. This was due to the reduction
100 stochastic simulations are plotted. A Active Gsk3b B Phospho-tau; C ROS. Key: blue= day 0; green=day 4; red =day 8; D orange= repeated
immunisation at Day 0 and Day 7; black = no immunisation.
doi:10.1371/journal.pone.0073631.g003
Table 1. Summary of parameter scans showing the effect of increasing the parameter value by a factor of two on the levels of Ab,
tau, glia and ROS.
Parameter name
DNA damage
response
Aggregation
process Soluble Ab Ab plaques Tau_P2 NFT Activated glia ROS
kactglia1 3 q
kactglia2 3 q
kaggTauP2 3 Q q
kbinAbantiAb 3 Q Q Q Q Q
kbinMTTau 3 Q Q
kdegAbeta 3 Q Q Q Q Q Q
kdegAntiAb 3 q q q q Q
kdephosTau 3 Q Q
kdimerAbeta 3 Q q Q Q q Q
kdisaggAbP1 3 Q Q Q Q Q Q
kgenROSPlaque 3 q q q q q q
kinactglia1 3 Q
kinactglia2 3 Q
kpf 3 Q Q Q Q Q Q
kpg 3 q q q q q q
kpghalf 3 Q Q Q Q Q Q
kphosTauGsk3bp53 3 q q
kprodAbeta2 3 q q q q q q
krelMTTau 3 q q
ksynTau 3 q q
kactATM 3 q q q q q q
kbinGsk3bp53 3 q q q q q q
kbinMdm2p53 3 Q Q Q Q Q Q
kdamROS 3 q q q q q q
kdegMdm2mRNA 3 q q q q q q
kdegp53mRNA 3 Q Q Q Q Q Q
kdephosMdm2 3 Q Q Q Q Q Q
kinactATM 3 Q Q Q Q Q Q
kMdm2Pub 3 q q q q q q
kphosMdm2 3 q q q q q q
krelGsk3bp53 3 Q Q Q Q Q Q
kremROS 3 Q Q Q Q Q Q
krepair 3 Q Q Q Q Q Q
ksynMdm2 3 Q Q Q Q Q Q
ksynMdm2mRNA 3 Q Q Q Q Q Q
ksynMdm2mRNAGsk3bp53 3 Q Q Q Q Q Q
ksynp53 3 q q q q q q
ksynp53mRNA 3 q q q q q q
ksynp53mRNAAbeta 3 q q q q q q
Key: Q 2-fold decrease in parameter value; q2-fold increase in parameter value.
doi:10.1371/journal.pone.0073631.t001
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in ROS levels after clearance of plaques. We used our model to
study the effect of passive and active immunotherapy of established
disease, and the use of immunotherapy as a preventive measure for
Alzheimer’s disease.
We chose to base our model on a cellular system and used a
time period of 12 days for the simulations. The main reason for
this choice is that is not currently feasible to run complex models
over long time periods using stochastic simulation since each
individual simulation would take many hours to complete and
many repeat simulations are required. Experimental cellular
models induce Ab aggregation by either the addition of Ab to
the extracellular fluid [38] or by the addition of rotenone [47]. In
both systems the kinetics of Ab aggregation is similar, with
aggregation being observed by 24 h and maximal aggregation by
2 days. The limitation of using a cellular model, (either
experimentally or in a computer model) is that it may not be
valid to extrapolate findings to human ageing. However, cellular
models do provide valuable information on the potential
underlying molecular mechanisms in the aggregation process
and can aid understanding of how interventions such as
immunisation can ameliorate the process. It would be possible to
adapt the current model to run simulations over longer timescales
to mimic human ageing if we used deterministic simulation and
modified the parameters involved in the aggregation process.
The model contains many parameters and so we carried out
parameter scans to examine which oness affect the levels of soluble
Ab, plaques, phospho tau, tangles, activated glia and ROS.
The parameters which are involved in DNA damage and the
DNA damage response (e.g. kdamROS, kactATM, krepair) had simulta-
neous affects on ROS levels, soluble Ab, plaques, phospho-tau and
tangles. This is due to the cycle of events and the self-amplifying
loop of an increase in GSK3b activity, Ab levels, ROS, p53
activation, further increased activity of GSK3 and hyperpho-
sphorylation of tau (Figure 4) and a detailed figure showing the key
reactions and parameters is included in the supplementary
information (Figure S5). This cycle has previously been described
in detail and showed how both familial and sporadic AD can be
explained by a unified hypothesis due to the fact that the cycle can
start at any point [48]. Breaking the cycle by immunisation will
reduce plaques but without altering other stress within the cell
which may lead to continued activation of p53 and GSK3b and
thus to hyperphosphorylation of tau and accumulation of tangles.
Table 2. Parameters ranked in order of their effect on Ab Plaques.
Rank Parameter name
Direction of
parameter change
% decrease in
maximum plaque
size
Rank for
soluble Ab
Direction of
parameter change
% decrease in
maximum soluble
Ab levels
1 kprodAbeta2 Q 97.91 1 Q 45.81
2 kdisaggAbP1 q 96.77 23 q 10.11
3 kbinGSK3bp53 Q 96.30 2 Q 39.30
4 krelGSK3bp53 q 96.29 3 q 39.29
5 kpghalf q 93.43 24 q 9.42
6 kpg Q 57.24 25 Q 5.61
7 ksynMdm2 q 53.02 5 q 24.96
8 kdegMdm2mRNA Q 51.81 6 Q 24.68
9 kbinMdm2p53 q 50.91 7 q 23.96
10 ksynp53 Q 50.46 8 Q 23.60
11 kdegp53mRNA q 49.94 11 q 23.49
12 kphosMdm2 Q 49.15 9 Q 23.58
13 kdephosMdm2 q 49.09 10 q 23.56
14 kMdm2PUb Q 48.29 12 Q 23.36
15 ksynp53mRNA Q 41.34 13 Q 19.59
16 kactATM Q 39.60 14 Q 17.90
17 kdamROS Q 39.60 15 Q 17.90
18 kinactATM q 38.71 17 q 17.64
19 kdegAbeta q 36.96 16 q 17.66
20 kremROS q 33.78 19 q 16.06
21 ksynMdm2mRNA q 33.09 18 q 16.78
22 kgenROSAbeta Q 33.00 21 Q 11.76
23 kpf q 29.87 27 q 2.54
24 krepair q 24.51 20 q 12.96
25 ksynMdm2mRNAGSK3bp53 q 22.13 22 q 11.44
26 kgenROSPlaque Q 5.03 26 Q 4.39
27 ksynp53mRNAAbeta Q 3.77 28 Q 2.32
28 kdimerAbeta Q 3.10 4 Q 28.69
Key: Q 2-fold decrease in parameter value; q2-fold increase in parameter value.
doi:10.1371/journal.pone.0073631.t002
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Although the exact neurotoxic species of tau has yet to be
conclusively identified [49], there is a general consensus that
abnormal and hyperphosphorylated tau has detrimental effects,
leading to loss of neurons, strongly suggesting that therapies which
just target Ab may not be beneficial. Additional interventions
which reduce cellular stress and/or reduce the activity of GSK3b
are likely to be required in order to slow down disease progression.
Our data with decrease of phospho tau without any changes in
tangles [10,17] and the absence of clinical improvement [11]
support this hypothesis.
We chose to focus on GSK3b and p53 due to the finding that
both proteins are upregulated in AD and the relevance of GSK3b
in AD [50,51]. There are likely to be many other pathways and
proteins involved, but we still lack knowledge of what is actually
important in the disease process. Other kinases are also involved in
tau phosphorylation, such as CDK5, and the effects of phosphor-
ylation on the affinity of tau for microtubules is much more
complex than we have modelled here [52]. However, there is still a
lot to learn about the details and it will be possible to modify our
model as new data emerge. Our model was originally developed to
test hypotheses about the assumed pathways [20] and we believe
Table 3. Parameters ranked in order of their effect on tangles.
Rank Parameter
Direction of
parameter change
% decrease in
maximum NFT level
Rank for effect on
phospho-tau
Direction of
parameter change
% decrease in
maximum phospho-tau
level
1 kbinGSK3bp53 Q 94.40 1 Q 72.26
2 krelGSK3bp53 q 94.40 2 q 72.25
3 kdephosTau q 92.65 3 q 70.60
4 kphosTauGsk3bp53 Q 92.13 4 Q 69.88
5 ksynMdm2 q 80.02 5 q 54.67
6 kdegMdm2mRNA Q 79.89 6 Q 54.67
7 kbinMdm2p53 q 78.66 7 q 53.33
8 kphosMdm2 Q 78.29 8 Q 53.20
9 kdephosMdm2 q 78.26 9 q 53.17
10 kMdm2PUb Q 78.16 10 Q 53.16
11 ksynp53 Q 77.91 11 Q 52.49
12 kdegp53mRNA q 77.84 12 q 52.49
13 ksynp53mRNA Q 72.03 13 Q 46.72
14 kactATM Q 69.75 16 Q 42.23
15 kdamROS Q 69.75 17 Q 42.23
16 kinactATM q 69.58 18 q 41.82
17 kbinMTTau q 68.72 14 q 43.29
18 kremROS q 68.55 20 q 38.84
19 krelMTTau Q 68.45 15 Q 43.04
20 krepair q 66.33 22 q 32.45
21 ksynMdm2mRNA q 65.00 19 q 41.02
22 kgenROSAbeta Q 63.49 24 Q 26.55
23 kprodAbeta2 Q 60.96 21 Q 33.24
24 ksynMdm2mRNAGSK3bp53 q 50.49 23 q 29.01
25 kaggTauP2 Q 47.42 34 Q 3.63
26 kbinAbantiAb q 47.42 35 q 3.63
27 ksynTau Q 28.75 26 Q 11.05
28 kdimerAbeta q 25.41 31 q 7.66
29 kdegAbeta q 23.76 25 q 15.83
30 kdisaggAbP1 q 12.31 28 q 9.06
31 ksynp53mRNAAbeta Q 10.67 33 Q 6.07
32 kpghalf q 10.39 29 q 8.92
33 kgenROSPlaque Q 8.13 27 Q 10.51
34 kpg Q 7.55 30 Q 8.72
35 kdegAntiAb Q 7.41 - Q 0.00
36 kpf q 6.10 32 q 6.77
Key: Q 2-fold decrease in parameter value; q2-fold increase in parameter value.
doi:10.1371/journal.pone.0073631.t003
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that further experiments to examine the role of GSK3b and p53 in
AD would increase our understanding of the processes involved.
We do not claim to have produced a model that encompasses all
aspects of the disease process and as for all simplified models, great
care should be taken when extrapolating data to the clinic.
However, it will be possible to extend the current model to include
additional pathways, as additional experimental and clinical data
emerge, to provide a more complete description. Another aspect of
the model that could be extended is the aggregation process. We
only included one pathway for Ab aggregation and assumed that
the building blocks of plaques are dimers [53] as we wanted to
keep the model as simple as possible, and there is controversy over
the actual mechanisms of aggregation in the brain. For example, it
has been suggested that low molecular mass oligomers extracted
from AD brain may be artefacts induced by the use of detergents
in the extraction process [54]. However, even if dimers are not
detected in the human brain, this does not preclude the possibility
that they are present at a level too low to detect but are important
in the aggregation process. As our model predicts that dimers are
very unstable and either dissociate into monomers or rapidly
aggregate. This means that levels of dimers may always be too low
to be detected. If desired, modelling could be used to test different
hypotheses of the aggregation process by building a set of models
with different schemes for the aggregation mechanism and then
comparing the model predictions.
An interesting extension of the model would be to include the
connection between Ab and synaptic activity. A recent study
suggests that synaptic activity leads to an increase in Ab
production via endocytosis, and that Ab inhibits synaptic activity
[55]. We hypothesise that including this negative feedback loop in
the model would keep both Ab levels and synaptic activity within
the normal range. It has been suggested that low levels of Ab may
have this functional role (reviewed in [56]), however, the negative
feedback loop may be disrupted in AD. For example, an increase
in Ab due to other pathways may lead to formation of Ab
oligomers and/or plaques which may interfere with synaptic
activity. When more information becomes available on the link
between Ab and synaptic activity, it will be possible to examine the
effect of disruption of the feedback loop on Ab secretion and
aggregation.
The disparity between the promising outcomes seen in
preclinical transgenic animal models and the disappointing results
of early phase clinical trials has necessitated additional reflection
on mode of action of Ab immunotherapy and the best strategies
for future clinical trials. Based on cognitive and pathological
measures it has been widely acknowledged that the best mouse
models fall short of fully recapitulating Alzheimer’s disease, but
this conclusion is made inescapable by the outcomes of the
immunotherapy trials carried out to date.
It could be argued that the current ‘‘gold standard’’ for a mouse
model would be the triple transgenic expressing clinically relevant
mutant isoforms of presenilin (M146V), amyloid precursor protein
(the Swedish mutation), and tau (P301L) [57]. Passive immunisa-
tion with Ab-specific antibodies provided clear benefit to triple
transgenic mice at the histological level [58]. Taken in isolation
this finding would not provide justification for a clinical trial (in
this study the antibody was delivered by direct injection into the
hippocampus, obviating issues relating to the blood brain barrier)
but is notable in the current context for its mechanistic insights.
Though the immunotherapy was directed at Ab there was a
reduction in tau pathology at early stages (the extensively
phosphorylated tau of later stages could not be cleared). These
data suggest that the passive Ab immunisation would be
efficacious before the formation of tau tangles, in agreement with
our simulations.
One unavoidable limitation of the best available transgenic
mouse models is that they incorporate mutations associated with
the inherited forms of AD, and may inadequately mimic the more
numerous sporadic forms of the disease (reviewed in [59]). Early
(presymptomatic) intervention in the form of active or passive
immunisation may be plausible in individuals deemed to be at high
risk of AD due to family history and/or genetic testing, but with
the currently associated risks and uncertain benefits, prophylactic
Ab immunisation is inconceivable. The situation may change as
models become available for sporadic AD. A recent report of a
‘‘natural’’ model (age-related changes strongly reminiscent of AD
in the rodent Octodon degus) may be grounds for optimism in this
regard [60].
The great advantage of the computational modelling approach
is the ease with which parameters can be updated and models
adapted as new information becomes available. In its current
form, our model is sensitive to changes in some (but not all)
parameters, and some of these parameters represent druggable
targets for which clinical and experimental data may be
forthcoming. As an example, it has already been demonstrated
that inhibition of GSK3b is neuroprotective in an AD mouse
model [61]. On the other hand, adverse effects of GSK3b
inhibition have also been reported to have neurotoxic effects in
mice models due to induction of apoptosis by nuclear factor of
activated T-cells (NFAT) [62]. Although it will be necessary to
extend our current model to test these effects, computer modelling
could be a powerful tool for examining the possible effects of
potential targets. There is also in vivo evidence for the protective
effects of antioxidants, including the natural plant phenol
resveratrol [63]. It would be relatively straightforward to adapt
the computer model to simulate such interventions, to predict
possible outcomes were such agents used together or in
combination with immunisation strategies, and to incorporate
Figure 4. Cycle of reactions leading to aggregation of Ab and
tau. Immunisation reduces aggregation of both Ab and tau by
breaking the cycle. However stress within the cell may still cause
activation of p53 and GSK3b so that the aggregation process of tau
continues.
doi:10.1371/journal.pone.0073631.g004
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findings from relevant clinical trials as their outcomes are
published.
Conclusions
This paper describes how our mathematical model can simulate
and predict the effects of Ab immunisation in Alzheimer’s disease.
We believe that the model will become increasingly accurate as
new mechanistic details of the relevant pathways become
available, and suggest that the mathematical model will be useful
in testing possible interventions prior to clinical trials.
Methods
Model construction
The model of Proctor & Gray [20] was modified to include
processes involved in Ab immunisation. Before describing how the
model was modified, we give a brief description of this model
which we refer to as the GSK3 model. The GSK3 model was
constructed to investigate the relationship between GSK3b, p53,
Ab and tau. It was built in a modular way and includes
components for DNA damage, p53 regulation, GSK3 activity,
Ab turnover, tau dynamics and the aggregation of Ab and tau. In
the module for p53 regulation we assumed that p53 binds to the
E3 ligase Mdm2 and is then ubiquitinated and targeted for
degradation by the 26S proteasome [64]. Under normal
(unstressed) conditions, both p53 and Mdm2 are kept at low basal
levels. The module for the DNA damage response includes detail
of p53 activation which occurs after DNA damage due to p53
phosphorylation which prevents p53 binding to Mdm2 and so it is
no longer degraded. When p53 levels are elevated it can bind to
GSK3b which increases the activity of both proteins [43,65]. In
the tau module, we assumed that tau is continuously being
phosphorylated (by GSK3b) [66] and dephosphorylated (by PP2)
[67]] to regulate its binding to microtubules. When GSK3b
activity is increased, more tau is phosphorylated and tau may then
start to aggregate. In the Ab turnover module we assumed that Ab
is continually produced and degraded but when GSK3b and p53
bind, the production of Ab is increased which in return increases
the production of p53. Although the precise mechanism of
increased Ab production via GSK3 is still not clear, studies have
shown that GSK3 inhibitors reduce APP processing (reviewed in
[68]). We also assumed that soluble Ab leads to an increase
reactive oxygen species (ROS) [22] which may then lead to further
DNA damage and increased activation of p53. This vicious cycle
of events has been described in a recent publication [48]. The full
details of the GSK3 model are available in an open access journal
[20] and the SBML code is available from the Biomodels database
(BioModels ID:BIOMD0000000286) [69]. The additional species
and reactions for the modified model are shown in Tables 4, 5,
and 6 and the assumptions made are detailed below.
Modelling the immunisation process
The exact mechanism by which Ab immunisation removes Ab
is not clear but it is likely to be several different pathways. Since
existing plaques are reduced after immunisation, it is assumed that
antibodies result in disaggregation of plaques with microglia
phagocytosing Ab. A study involving APP transgenic mice suggests
that there is a two phase mechanism of Ab clearance after
administration of antibodies [70]. The first phase occurs 4–
24 hours after immunisation and is independent of microglial
activation and results in clearance of diffuse Ab deposits. The
second phase, which occurs between 1 and 3 days, involves
clearance of amyloid plaques in association with activation of
microglia.
We modified our previous model by adding a species named
‘‘antiAb’’ to represent the addition of antibodies (i.e. passive
immunisation) and another species named ‘‘Glia’’ to represent
microglia.
To model the addition of antibodies at different time-points, we
assumed that initially antiAb= 0 and used an event structure in the
SBML code so that when the simulation time is equal to the
chosen time of the intervention, antiAb is set to 50. We also
modelled active immunisation and in this case, included a reaction
for antiAb production to ensure that antibodies were continually
produced.
Note that for simplicity we have ignored spatial aspects in this
model at present. The following assumptions were made
concerning the role of glia and antibodies:
N Glia can be in four states: inactive (GliaI), partially active glia
(GliaP1, and GliaP2) which are attracted to plaques but do not
engulf them [71] and active (GliaA) which are activated by
immunotherapy [72]. We included two pools of partially
activated glia in order to provide a longer time lag between
partial and full activation. Initially all glia are inactive (i.e. not
able to phagocytose Ab significantly).
N The presence of plaques is required for partial activation of
glia [71].
N The presence of antibodies is required for full activation of glia
[72].
N Active or partially active glia can be inactivated [73].
N Fully active glia can bind to plaques and degrade them by
phagocytosis [70].
N Active glia bound to plaques can generate ROS [74].
N Antibodies can disaggregate plaques [75].
N Antibodies enhance the degradation of soluble Ab [76].
N Antibodies can be degraded (to mimic diffusion from cell).
The role of glia is still poorly understood and there is
controversy over whether they are neuroprotective or neurotoxic
[77]. From our assumptions we have included both effects of glia.
On the one hand they are able to degrade plaques by phagocytosis
but on the other hand, they increase the ROS production when
bound to plaques.
Kinetics of aggregation
We assume that the aggregation process starts with the
formation of Ab dimers from two monomers but that this reaction
is reversible. We represent monomers and dimers by the species
Abeta and AbDim, respectively in this model. In our previous
GSK3-p53 model, we used the name AggAbeta to represent Ab
dimers but changed this terminology to be consistent with a recent
model of Ab aggregation [41]. Similarly we renamed the reactions
and parameters. There is controversy over the role of dimers and
small oligomers in the aggregation process since there is limited
direct evidence of their existence in AD. Although they are
extracted from AD brain, they may represent artefacts induced by
the peptide’s interaction with detergent [54]. Interestingly, our
model predicts that levels of dimers are always very low (close to
zero) . This is due to the assumptions that either dimers dissociate
into monomers or rapidly initiate the aggregation process.
Many different schemes of the actual aggregation process from
monomers to plaques have been proposed and modelled. The
formation of a new plaque has been shown to be nucleation
dependent leading to a lag phase. In an in vitro system as modelled
Computer Modelling of Alzheimer’s Disease
PLOS ONE | www.plosone.org 12 September 2013 | Volume 8 | Issue 9 | e73631
here, the lag phase is relatively short (about 1 day) whereas in a
human brain this would be on timescales many years. Once a
plaque has formed, further growth is governed by first-order
kinetics [78]. Different deposition mechansims have been
proposed including monomers, dimers or preassemble oligomers
[79]. In order to keep the model as simple as possible, we only
included one pathway, and based on fairly recent experimental
data, we assumed that dimers are the building blocks of aggregates
[53]. However, our model could be adapted to add other pathways
if desired.
Our previous model assumed that plaque formation was
irreversible and so once the aggregation process started, the
model predicted that plaques form rapidly and continue to grow.
However, studies show that although plaques do form quickly,
they soon reach a maximum size where no further growth is
observed [80,81]. Since soluble Ab is continually produced, this
observation suggests that plaque growth is not irreversible but that
disaggregation takes place. This means that plaques are dynamic
structures in which Ab is being continually deposited and removed
and when these two processes are in balance, the plaque appears
to be stable. Previous modelling suggests that plaques are porous
and so the disaggregation rate depends on the size of the plaque
[82]. Therefore we use mass action kinetics to model plaque
disaggregation, which means that the rate is proportional to the
size. The rate of plaque growth depends on the level of soluble Ab
and it may be considered that it also depends on plaque size, since
we might assume that large plaques have a greater chance of
sequestering more Ab than small plaques. However with this
assumption the rate of growth would always be greater than the
rate of disaggregation (unless the production of Ab ceased).
Therefore we assume that plaque growth initially increases linearly
with plaque size but then reaches a maximum rate. We use a Hill
Table 4. Additional species for the immunotherapy model. All other species in the model are given in Proctor & Gray [20].
Species id Description Initial value
GliaI Inactive glia 100
GliaP1, GliaP2 Glia associated with plaques but not able to phagocytose 0
GliaA Active glia which can phagocytose 0
antiAb Antibody against amyloid-beta 0
AbP_GliaA Abeta plaque bound to active glia 0
Abeta_antiAb Abeta monomer bound to antibody 0
AbDim_antiAb Abeta dimer bound to antibody 0
AbDim Abeta dimer (replaces species AggAbeta) 0
AbP Abeta plaques (replaces species AbetaPlaque) 0
doi:10.1371/journal.pone.0073631.t004
Table 5. Additional reactions for the immunotherapy model. All other reactions in the model are given in Proctor & Gray [20].
Reaction id Reactants Products Kinetic rate law
Glia ActivationStep1 GliaI, AbP GliaP1, AbP kactglia1*GliaI*AbP
Glia ActivationStep2 GliaP1, AbP GliaP2, AbP kactglia1*GliaP1*AbP
Glia ActivationStep2 GliaP2, antiAb GliaA, antiAb kactglia2*GliaP2*antiAb
GliaInactivationStep1 GliaA GliaP2 kinactglia1*GliaA
GliaInactivationStep2 GliaP2 GliaP1 kinactglia2*GliaP2
GliaInactivationStep3 GliaP1 GliaI kinactglia2*GliaP1
AbetaPlaqueBindingToGlia GliaA, AbP AbP_GliaA kbinAbetaGlia*GliaA*AbP
AbetaPlaqueReleaseFromGlia AbP_GliaA GliaA, AbP krelAbetaGlia*AbP_GliaA
PlaqueClearanceByGlia AbP_GliaA GliaA kdegAbetaGlia*AbP_GliaA
ROSgenerationByGlia AbP_GliaA AbP_GliaA, ROS kgenROSGlia*AbP_GliaA
ROSgenerationByPlaques AbP AbP, ROS kgenROSplaque * AbP
AntiAbRemoval antiAb Sink kdegAntiAb*antiAb
AntiAbBindingToAbeta Abeta,antiAb Abeta_antiAb kbinAbantiAb*Abeta*antiAb
AntiAbBindingToAbetaDimers AbDim,antiAb AbDim_antiAb kbinAbantiAb*AbDim*antiAb
AbetaDegradationViaAntiAb Abeta_antiAb antiAb kdegAbetaAntiAb*Abeta_antiAb
AbetaDimerDegradViaAntiAb AbDim_antiAb antiAb kdegAbetaAntiAb*AbDim_antiAb
PlaqueDisaggregation AbP Abeta kdisaggAbeta1*AbP
PlaqueDisaggregationViaAntiAb AbP, antiAb Abeta,antiAb kdisaggAbeta2*AbP*antiAb
AbetaDedimerisation AbDim Abeta kdedimer * AbDim
doi:10.1371/journal.pone.0073631.t005
Computer Modelling of Alzheimer’s Disease
PLOS ONE | www.plosone.org 13 September 2013 | Volume 8 | Issue 9 | e73631
function to model this as in our previous model of Ab aggregation
(see Figure 10 of [41]). The chosen parameters for plaque growth
and plaque disaggregation resulted in a maximum plaque size of
75. In reality, plaques are much larger but it was necessary to use
relatively low numbers for all the molecules in our model, so that
we could carry out simulations within reasonable time-frames. We
also speeded up the aggregation process to mimic an experimental
cellular system. If we modelled the process over much longer time
periods to represent the ageing process, then the aggregation
process would be slower and larger plaques would form. Since we
examined all the parameters to see which ones had most effect on
plaque size, it would be straight-forward to modify parameter
values in order to obtain larger plaques if desired (see Results
section and Table 2). We also included a reaction for ROS
generation via plaques, in addition to our previous modelled
reactions for ROS generation via soluble Ab, since recent data
shows that ROS can be produced by Ab in all aggregation states
[21].
Ab turnover
We assume that Ab is continually produced and degraded and
that normally Ab levels are kept at low basal levels. We also
assume that if p53 activity is increased via its interaction with
GSK3b, then production of Ab is increased [83]. However, more
importantly, it has been observed that Ab degradation is impaired
in AD [39]. We previously modelled turnover and aggregation
kinetics of Ab and found that we needed to assume that the rate of
Ab degradation declines with age in persons which develop AD
[41]. This is a reasonable assumption, since it has also been shown
that neprilysin, a major Ab-degrading enzyme declines with age
[84,85]. Therefore we also assume a lower rate of Ab degradation
in AD.
The maximum size of plaque is mainly determined by the
amount of soluble Ab and so parameters which have greatest affect
on plaque size include Ab production and clearance rates. We
used the rates from an experimental study which looked at levels of
Ab in the cerebrospinal fluid (CSF) [39]. They found that the rate
of Ab production (1.86e25 molecules s21) was the same in AD
subjects and age-matched normal controls but that the degrada-
tion rate was lower in AD patients (1.5e25 s21 in AD compared to
2.125 s21 for controls). It should be noted that both the production
and degradation rate of Ab is likely to be higher in neurons than in
the CSF but it is the ratio of production/degradation which is
more important in determining levels of soluble Ab rather than the
individual rates. We assumed that this ratio is the same in neurons
as the CSF and so do not believe that even if we had data for
actual rates in neurons that it would not make any qualitative
differences to the model predictions. Therefore we used the AD
degradation rate from this study and then adjusted the parameters
for aggregation so that plaques start to form by about 2 days and
reach a maximum size by about day 10. This was to allow the
model to be simulated in a reasonable amount of time. However,
this meant that plaques still formed even with the observed mean
degradation rate in the normal controls. We found that we needed
to set the normal degradation rate an order of magnitude higher
than the AD rate. We previously built an individual module of Ab
turnover and aggregation in which we used the rates from the data
for both normal and AD cases as we were able to run this model
over a time scale of 100 years. However, in this model, we needed
to assume that the degradation rate declines with age in the AD
patients, (a more reasonable assumption than a constant lower
degradation rate since birth). In the current model, in which we
speed up the aggregation process over a time scale of days, we
assume a constant degradation rate for AD, since ageing effects are
not modelled here.
Parameter scans
We carried out all the parameter scans using COPASI [86]and
anaylsed the results in the R statistical package. Note that all
parameters scans were carried out with slightly different values to
three of the parameters (kgenROSAbeta=2e-5, kgenROSGlia=1e-5,
kgenROSPlaque=1e-5) which resulted in slightly lower levels of AbP,
Table 6. Values for additional parameters in the immunotherapy model. All other parameters in the model are given in Proctor &
Gray [20].
Parameter Value Comment
kactglia1 6.0e-7 molecule
21s21 Partial activation of microglia increases linearly with plaque levels.
kactglia2 6.0e-7 molecule
21s21 Full activation of microglia takes about 1–2 days after addition of antibodies
kbinAbantiAb 1.0e-6 molecule
21s21 Soluble Ab binds to antibodies within a few hours after their addition.
kbinAbPGlia 1.0e-5 molecule
21s21 Fully activated pool of microglia bind to plaques within 15–30 minutes
kdedimerAbeta 1.0e-6 s
21 Rate of disassociation of dimers to monomers is assumed to be low so that aggregation will start within one to
two days.
kdegAbetaAntiAb 1.5e-4 s
21 We assumed that antibodies increase Ab degradation rate by an order of magnitude.
kdegAbPGlia 5.0e-3 s
21 Plaques associated with fully activated microglia are rapidly degraded via phagocytosis.
kdegAntiAb 2.75e-6 s
21 Half-life of antibodies <3 days.
kdisaggAbP1 2.0e-4 s
21 Rate chosen to give a maximum plaque size of about 80.
kdisaggAbP2 1.0e-6 molecule
21s21 Antibodies disaggregate plaques at lower rate than normal.
kgenROSGlia 2.0e-5 s
21 Microglia generate ROS at slightly lower rate as Ab.
kgenROSPlaque 2.0e-5 s
21 Plaques generate ROS at same rate as glia.
kinactglia1 5.0e-6 s
21 Inactivation occurs with a half-life of about 4 days.
kinactglia2 5.0e-6 s
21 Inactivation occurs with a half-life of about 4 days.
krelAbPGlia 5.0e-5 s
21 The release of Ab from microglia without phagocytosis has lower probability than degradation of Ab via
activated microglia.
doi:10.1371/journal.pone.0073631.t006
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NFT, Abeta,Tau_P2, Glia_A and ROS than those shown in
Figures S3 and S4. However, we made our comparisons to the
maximum values of the species with these default parameters so
that the ranking and percentage changes are not affected.
Details of model code and simulation
The model was encoded in the Systems Biology Markup
Language(SBML) [36], a computer-readable format for network
models using the SBML shorthand tool [87]. SBML is a modelling
standard that allows models to be easily modified or extended. The
code is publicly available from the Biomodels database (Biomodels
ID: MODEL1212030000) [69] and is available as a supplemen-
tary file (Code S1). Simulations were carried out using the
Gillespie algorithm [88] which is a method for doing exact
stochastic simulation. Simulation data was plotted in R using the
ggplot2 package [89].
Supporting Information
Figure S1 Individual plots for model with low Ab
degradation rate and no immunisation. Six runs from
100 simulations are plotted. Key: orange = soluble Ab; blue =Ab
plaques; green = phospho-tau; black = tau tangles; red = activated
glia.
(TIF)
Figure S2 Model predictions for levels of Ab, tau,
activated glia under different simulated interventions
using a deterministic model. A–D Simulated passive
immunisation administered at different time-points: A Day 0; B
Day 4; C Day 8; D Repeated immunisation at Day 0 and Day 7. E
Simulated active immunisation. F No immunisation. Key:
orange = soluble Ab; blue =Ab plaques; green = phospho-tau;
black = tau tangles; red= activated glia.
(TIF)
Figure S3 Varying model parameters, part 1. Effect of
varying a selection of model parameters from half to double its
initial value. The thickness of the line is scaled to the parameter
value with thicker lines representing higher values. A kactglia2; B
kbinAbetaGlia; C kbinMTTau; D kdegAbeta; E kdegAntiAb; F kdephosTau; G
kgenROSPlaque; H kpf. Key: orange = soluble Ab; blue =Ab plaques;
green =phospho-tau; black = tau tangles; red = activated glia,
purple =ROS.
(TIF)
Figure S4 Varying model parameters, part 2. Effect of
varying a selection of model parameters from half to double its
initial value. The thickness of the line is scaled to the parameter
value with thicker lines representing higher values. A kpg; B
kprodAbeta2; C kactATM; D kbinGsk3bp53; E kbinMdm2p53; F kdamROS; G
kremROS; H krepair; . Key: orange= soluble Ab; blue =Ab plaques;
green =phospho-tau; black = tau tangles; red = activated glia,
purple =ROS.
(TIF)
Figure S5 Key components of the model network.
Network diagram of the key components in the model network
showing the reactions involving the most sensitive parameters. The
labels on the reaction arrows starting with ‘P’ or ‘T’ indicate the
rank of the parameter with respect to its effect on the maximum
level of plaques and tangles respectively.
(TIF)
Code S1 SBML code. This file contains the SBML code for the
model in which passive immunisation was mimicked at day 4 after
the start of the simulation.
(XML)
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